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The devil facial tumor disease (DFTD) is caused by clonal transmissible cancers that have 
led to a catastrophic decline in the wild Tasmanian devil (Sarcophilus harrisii ) population. 
The first transmissible tumor, now termed devil facial tumor 1 (DFT1), was first discov-
ered in 1996 and has been continually transmitted to new hosts for at least 20 years. 
In 2015, a second transmissible cancer [devil facial tumor 2 (DFT2)] was discovered in 
wild devils, and the DFT2 is genetically distinct and independent from the DFT1. Despite 
the estimated 136,559 base pair substitutions and 14,647 insertions/deletions in the 
DFT1 genome as compared to two normal devil reference genomes, the allograft tumors 
are not rejected by the host immune system. Additionally, genome sequencing of two 
sub-strains of DFT1 detected greater than 15,000 single-base substitutions that were 
found in only one of the DFT1 sub-strains, demonstrating the transmissible tumors 
are evolving and that generation of neoantigens is likely ongoing. Recent evidence in 
human clinical trials suggests that blocking PD-1:PD-L1 interactions promotes antitumor 
immune responses and is most effective in cancers with a high number of mutations. We 
hypothesized that DFTD cells could exploit the PD-1:PD-L1 inhibitory pathway to evade 
antitumor immune responses. We developed recombinant proteins and monoclonal 
antibodies (mAbs) to provide the first demonstration that PD-1 binds to both PD-L1 and 
PD-L2 in a non-placental mammal and show that PD-L1 is upregulated in DFTD cells 
Abbreviations: DFTD, devil facial tumor disease; DFT1, devil facial tumor 1; DFT2, devil facial tumor 2; cRF10, complete 
RPMI supplemented with 10% FBS; cRF5, complete RPMI supplemented with 5% FBS; mAbs, monoclonal antibodies; ECDs, 
extracellular domains; TMDs, transmembrane domains; ICDs, intracellular domains.
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inTrODUcTiOn
In 1996, a clonal, transmissible tumor was identified in wild 
Tasmanian devils, Sarcophilus harrisii (1), in northeastern 
Tasmania and has since spread across Tasmania. This devil facial 
tumor disease (DFTD) has been a primary cause of a devastating 
decline in the wild Tasmanian devil population (2). In 2015, a 
second transmissible tumor [devil facial tumor 2 (DFT2)] was 
discovered in wild devils and will undoubtedly hamper conserva-
tion efforts for the iconic species (3). Extensive monitoring of the 
wild population has shown that the devil facial tumor 1 (DFT1) is 
nearly always fatal once established in a host, and DFT2 appears 
to have similar lethal effects. A successful breeding program has 
led to the establishment of an insurance population of Tasmanian 
devils, but release of devils from the insurance population into the 
wild may prove futile until a vaccine that can protect against the 
DFTD is developed.
One of the initial hypotheses offered to explain the transmis-
sible nature of the DFT1 was that the low genetic diversity of the 
island population of Tasmanian devils allowed the transmissible 
tumors to be viewed as self, rather than foreign, by the host 
immune system (4, 5). However, the genome of two DFT1 
cell lines that were thoroughly analyzed had 136,559 base pair 
substitutions and 14,647 insertions/deletions as compared with 
two normal devil reference genomes. Furthermore, several stud-
ies have now demonstrated that the devils do contain sufficient 
genetic diversity to mount strong immune responses to foreign 
tissue (6, 7), including the ability to reject skin allografts but not 
reject skin autografts (8). Genome sequencing of two sub-strains 
of DFT1 detected greater than 15,000 single-base substitutions 
that were found in only one of the DFT1 sub-strains (9), demon-
strating that the transmissible tumors are evolving.
Analysis of human cancers has led Blank et al. (10) to suggest 
that “foreignness can likely be guaranteed for cancers with high 
mutational loads,” which leads to a relative abundance of neo-
antigens. The genetic mismatch due to host–tumor differences 
and ongoing generation of somatic mutations in the transmissible 
tumors should provide suitable neoantigen targets for host anti-
tumor responses, yet the devil immune system fails to reject both 
DFT1 and DFT2 cells. A primary means of immune evasion by 
the DFT1 is via downregulation of genes associated with antigen 
processing and presentation, such as β2-microglobulin (B2m) 
(11, 12). As a result, MHC class I (MHC I) is not expressed on 
the surface of DFT1 cells, but cell surface expression of MHC 
I can be upregulated by IFN-γ (11). One potential downside to 
IFN-γ stimulation is that powerful inhibitory cell surface signal-
ing molecules, such as PD-L1, are also upregulated in response to 
IFN-γ signaling in a wide variety of human, mouse, and canine 
tumors (13–15). Indeed, the correlation between PD-L1 and 
IFN-γ was 100% in human melanocytic lesions (16). PD-L1 can 
also be upregulated by IFNα/β, GM-CSF, IL-4, IL-10, and VEGF 
in mice and humans [reviewed in Ref. (17)] on a variety of cell 
types, including epithelial cells, endothelial cells, myeloid DCs, 
tumor-associated macrophages, and myeloid-derived suppressor 
cells [reviewed in Ref. (13)], all of which are capable of inhibiting 
antitumor responses (18, 19).
Immunotherapy that blocks checkpoint molecule interac-
tions, such as the PD-1:PD-L1 interaction, has achieved 10–87% 
response rates in a broad range of late-stage human cancers 
(20–22). Recent evidence suggests that blocking PD-1:PD-L1 
signaling promotes antitumor responses by releasing preexisting 
CD8 T cells from inhibitory signaling between PD-1 and PD-L1 
[reviewed by Tumeh et al. (23) and Rizvi et al. (24)]. Additionally, 
Le et  al. (25) have recently shown that tumors with extensive 
somatic mutation are more susceptible to immune checkpoint 
blockade immunotherapy, where the high mutation group (1,782 
mutations on average) had a 40% response rate and the low muta-
tion group (73 mutations on average) had no objective responses 
to PD-1 blockade colorectal cancer treatment. Additionally, PD-1 
signaling has been shown to play a key role in graft survival in 
mice (26), thus making the DFTs, which are essentially tissue 
allografts, an attractive target for PD-1:PD-L1 immunotherapy.
The lack of devil-specific antibodies for flow cytometry and 
immunohistochemistry (IHC) has been a major obstacle in 
understanding the role PD-1:PD-L1 signaling, and immune 
function in general in devils. Here, we have developed a panel 
of α-PD-1 and α-PD-L1 monoclonal antibodies (mAbs) that are 
highly specific for devil proteins and are capable of blocking PD-1 
binding to PD-L1 and PD-L2. We used these new mAbs to show 
that PD-L1 is strongly upregulated on DFT1 and DFT2 by IFN-γ 
in vitro and that PD-L1 was detected in the microenvironment 
DFT1 via IHC.
MaTerials anD MeThODs
Tasmanian Devil Tissue samples
Tasmanian devil PBMCs, tissues, and cell lines were collected 
with appropriate approvals from the Tasmanian Devil Captive 
Research Advisory Group, Tasmanian Government Department 
of Primary Industries, Parks, Water and the Environment 
(DPIPWE), Animal Ethics Committees from the University 
of South Australia (# U18-14), and the University of Tasmania 
(A0012513 and A0014976) and were performed in accordance 
in response to IFN-γ. Immunohistochemistry showed that PD-L1 is rarely expressed in 
primary tumor masses, but low numbers of PD-L1+ non-tumor cells were detected in the 
microenvironment of several metastatic tumors. Importantly, in vitro testing suggests that 
PD-1 binding to PD-L1 and PD-L2 can be blocked by mAbs, which could be critical to 
understanding how the DFT allografts evade the immune system.
Keywords: transmissible tumor, inhibitory checkpoint molecule, DFTD, wild immunity, PD-1, PD-l1, marsupial, 
allograft
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with relevant guidelines and regulations. PBMCs were isolated 
by diluting 1:1 with PBS, layering on Histopaque at room tem-
perature, and centrifuging at 400 g for 30 min. The PBMC layer 
was then collected and washed 2× with RPMI at 500 g for 5 min. 
Formalin-fixed paraffin-embedded (FFPE) tissue sections were 
collected and processed as reported previously (3, 27).
cells and cell culture conditions
Devil facial tumor 1 cell lines C5065, 1426, and 4096, the DFT2 
cell line JV, and devil PBMCs were cultured at 35°C in 5% CO2 
in complete RPMI supplemented with 10% FBS (cRF10), 2 mM 
l-glutamine, penicillin–streptomycin (100  U/ml and 0.1  mg/
ml), 10 mM HEPES, and 0.5 mM β-mercaptoethanol. Chinese 
hamster ovary (CHO) cells were cultured at 35°C with 5% CO2 
in 5% complete RPMI supplemented with 5% FBS (cRF5). For 
production of recombinant proteins, stably transfected CHO 
cells were cultured in suspension in spinner flasks in chemically 
defined, serum-free CHO Ex-Cell (Sigma # 14361C) media sup-
plemented with l-glutamine and penicillin–streptomycin.
identification and analysis of Devil PD-1, 
PD-l1, PD-l2, and iFn-γ genes
Full-length translated gene sequences for Ensembl transcripts: 
PDCD1-201 ENSSHAT00000018586 (PD-1), CD274-201 ENSS 
HAT00000003059 (PD-L1), PDCD1LG2 ENSSHAG00000004176 
(PD-L2), and IFNG ENSSHAT00000017850 (IFN-γ) were 
analyzed using the Phobius web server (28) and TMHMM web 
server (29) to predict membrane topology and SignalP 4.1 server 
(30) and Phobius to predict signal peptides. The ExPASy server 
ProtParam tool (31) was used to predict molecular weight and 
extinction coefficients, and the Eukaryotic Linear Motif resource 
(32) was used to predict immunoreceptor tyrosine-based inhibi-
tory motif (ITIM) and immunoreceptor tyrosine-based switch 
motif (ITSM) sites. Predicted protein structures were confirmed 
by alignment with protein sequences in several other mammalian 
species (Figures 1–3) using CLC Sequence Viewer (33) with the 
“gap open cost” set to 10, the “gap extension cost” set to 1, and 
the “end gap cost” set to “cheap.” The sequences that we used 
to make surface-expressed proteins have been deposited in the 
GenBank database with the following accession numbers: PD-1 
(KY075915), PD-L1 (KY075916), and PD-L2 (KY075917).
Pcr on cDna from PBMcs and Tumor 
cells
Primers for PD-1, PD-L1, and PD-L2 were developed for insert-
ing either full-length or extracellular domains (ECDs) into 
expression vectors (see Table S1 in Supplementary Material for 
a full list of primers). Total RNA was extracted from DFT1 cell 
line C5065 with or without 24 h stimulation with supernatant 
containing devil IFN-γ from CHO cells stably transfected with 
the pAF23 vector (devil IFN-γ). Devil PBMCs were stimulated 
overnight with ConA (5  μg/ml) prior to mRNA extraction. 
mRNA was reverse transcribed into cDNA using ProtoScript 
II First Strand cDNA Synthesis Kit (New England Biosciences). 
Qualitative assessment of PD-L1 expression in devil PBMCs 
and IFN-γ treated and untreated DFT1 C5065 was performed 
by amplifying a 280 bp segment of PD-L1 from cDNA. GAPDH 
was used as a reference gene and B2m was used as a positive 
control for IFN-γ effects. Primers used were as follows: cade-
GAPDH_F1 and cadeGAPDH_R1 for GAPDH, B2Mex1F and 
B2Mex2R for B2m, and deB7H1_318_F and deB7H1_597_R for 
PD-L1. Reactions were performed following the manufacturer’s 
recommendations for Kapa HiFi HotStart ReadyMix (Kapa 
Biosystems # KK2602), and cycling conditions consisted of an 
initial denaturing step of 95°C for 3 min, followed by 30 cycles 
of 98°C for 20  s, 60°C for 20  s, and 72°C for 20  s, and a final 
extension step at 72°C for 5 min. Reaction products were then 
run on a 1% agarose gel at 100 V.
Plasmid construction
pHULK piggyBac mammalian expression vectors (DNA2.0 
pJ507-02) were digested with BsaI for 1 h at ambient temperature 
and gel purified to create linear vectors for cloning. In order to 
expedite subsequent cloning and development of recombinant 
fusion proteins, we used overlap PCR extension and T4 ligase 
cloning techniques to create a modified pAF07 vector that 
contained bicistronic green fluorescent protein (GFP) and IRES-
DsRed, which included additional restriction sites (XbaI, BamHI, 
XhoI, NheI, and SalI). All expression vectors included the Kozak 
consensus sequence GCCGCCACC upstream of the start codon 
to ensure efficient initiation of the translation process (34).
In order to test our recombinant protein production approach, 
we first developed a vector that coded for devil IFN-γ (pAF23). 
Following confirmation that our recombinant devil IFN-γ was 
capable of upregulating B2m on of DFT1 cells in vitro [in Ref. 
(11)], we created the pAF27 vector that fused the devil IFN-γ 
signal peptide, an XbaI restriction site, GFP, an a SmaI restriction 
site, a (G4S)2 linker, a 6xHis-tag, and a SalI restriction site. All 
subsequent 6xHis-tagged fusion proteins (PD-1-His, PD-L1-His, 
and IFN-γ-His) were made by digesting pAF27 with XbaI + SmaI 
to remove the GFP coding region, and using Gibson Assembly 
(NEB # E5510S) following the manufacturer’s instructions 
to insert IFN-γ or the ECDs of PD-1 or PD-L1. Plasmids for 
full-length molecules including the transmembrane domains 
and intracellular domains (ICDs) (e.g., PD-L1 full-length) 
were cloned into XbaI +  SalI digested pAF07 (see Table S1 in 
Supplementary Material for primers). Additionally, we generated 
PD-1-ECD fused to human IgG1-Fc (PD-1-Fc) by digesting a 
pFUSE vector (Invivogen # pFUSE-hIgG1-Fc2) with NcoI and 
recombinant shrimp alkaline phosphatase (NEB # M0371S) and 
then using Gibson Assembly to ligate PD-1-ECD into the vec-
tor. All assembled plasmids were transformed into NEB 5-alpha 
competent Escherichia coli (NEB # C2987) following the manu-
facturer’s recommendation. Plasmid DNA was then sequenced by 
Australian Genome Research Facility (AGRF) and aligned using 
SnapGene® software (GSL Biotech).
Transfection and generation of 
recombinant cell lines
Stably transfected CHO cell lines expressing full-length surface 
proteins (PD-1, PD-L1, and PD-L2) and secreted proteins 
(IFN-γ, PD-1-His, PD-1-Fc, and PD-L1-His) were developed 
FigUre 1 | alignment of PD-1 amino acid sequence in eight mammalian species. The black-to-white color gradient indicates the degree of amino acid 
conservation among species, with black boxes indicating the most highly conserved sequence regions and white boxes indicating the most divergent regions for 
devil PD-1. Dashes indicate gaps that have been introduced for best-fit multiple-sequence alignments. The putative extracellular domains, transmembrane domains, 
intracellular domains, immunoreceptor tyrosine-based inhibitory motif, and immunoreceptor tyrosine-based switch motif (ITSM) are denoted by lines above the 
sequence. The devil PD-1 ITSM shares 100% identity with all species except mouse, opossum, and platypus.
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using a protocol modified from Matasci et al. (35) and Hsu and 
Uludag (36). Briefly, adherent CHO cells were cultured overnight 
in 6-, 12-, or 24-well plates until the adherent cells reached 
40–80% confluency. Plasmid DNA for transfection was diluted 
in a microfuge tube to 1 μg per 1 ×  106  cells to be transfected 
in 150 mM NaCl or serum-free RPMI and incubated for 2 min. 
Twenty-five kilodalton linear polyethylenimine (Polysciences # 
23966-2) was added to the DNA at a 3:1 ratio, and the solution 
was vortexed and incubated for 15–30 min at ambient tempera-
ture before the solution was added to the adherent cells. The cells 
were then incubated for 2–4 h before the media were removed 
and replaced with cRF10. The following day, the transfected cells 
were subjected to selection with hygromycin (1  mg/ml) for at 
least 7 days, and then maintained with 0.2 mg/ml of hygromycin.
Purification of recombinant Proteins
After reaching 60–80% confluence in T175 flasks in cRF5 
medium, the transfected CHO cells secreting recombinant 
fusion proteins were transferred directly to 50 ml CHO Ex-Cell 
media (Sigma # 14361C-1000ML) and cultured in magnetically 
stirred propeller flasks at 75 rpm. The density of cells was then 
maintained between 5 × 105 and 5 × 106 cells/ml by adding fresh 
media. Supernatant was collected and centrifuged at 3,200 rcf 
for 10 min at 4°C to remove cells and debris. The supernatant 
containing His-tagged proteins was then diluted 1:1 with 20 mM 
sodium phosphate buffer to a pH of 7.4. The diluted supernatant 
was then loaded onto HisTrap Excel columns (GE Health Care # 
17-3712-05), and the proteins were eluted using 20 mM sodium 
phosphate buffer with 0.5  M imidazole. Fusion proteins were 
then dialyzed in PBS using 6–8  kDa dialysis cassettes (Sigma 
# PURX60005) and then concentrated by evaporation in the 
dialysis cassette, aliquoted, and frozen until further use. The 
molecular weight and extinction coefficients for each protein 
were calculated using the ExPASy Bioinformatics Resource 
Portal tools (37). Protein concentration was determined 
using the appropriate molecular weight (kDa) and extinction 
FigUre 2 | alignment of PD-l1 amino acid sequence in eight mammalian species. The black-to-white color gradient indicates the degree of amino acid 
conservation among species, with black boxes indicating the most highly conserved sequence regions and white boxes indicating the most divergent regions for 
devil PD-L1. Dashes indicate gaps that have been introduced for best-fit multiple-sequence alignments. The putative extracellular domains, transmembrane 
domains, intracellular domains, and signal peptides are denoted by lines above the sequence.
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coefficient (ϵ/1,000) settings on a Nanodrop spectrophotometer. 
PD-1-Fc was cultured in cRF5, and the supernatant was used 
directly for in vitro FACS analysis.
Development of antibodies
Immunization of BALB/c mice for antibody production was 
approved by the University of South Australia Animal Ethics 
Committee (# 139/13) and the University of Tasmania Animal 
Ethics Committee (# A0014680) and was performed in accord-
ance with relevant guidelines and regulations. Mice were immu-
nized subcutaneously on each flank and the back of the neck 
with a total of 100 μg of fusion proteins (i.e., devil PD-L1-His) 
in a SqualVax (Oz Biosciences # SQ0010) emulsion on days 0 
and 14. At least 14 days after the day 14 booster, the mice were 
intravenously administered 100 μg of fusion proteins. Four or five 
days following the intravenous booster, the mice were humanely 
killed and the spleen and lymph nodes (LN) were harvested. 
Hybridomas were produced using SP2/0 mouse myeloma cells as 
the fusion partner and following a standard polyethylene glycol 
hybridoma fusion protocol (38, 39). Briefly, following hybridoma 
fusion, the cells were cultured for 1  day in complete Iscove’s 
Modified Dulbecco’s Medium (IMDM) (1% non-essential amino 
acids, 100  U/ml penicillin–streptomycin, 2  mM l-glutamine, 
50 μM β-ME, and 10 mM HEPES) with 20% FBS, and hybridoma 
fusion and cloning supplement (Roche # 11363735001). One day 
postfusion, HAT media supplement (Sigma # H0262-10VL) was 
added to the culture.
Hybridomas were initially screened for antibody binding 
to fusion proteins via ELISA, and results were confirmed via 
flow cytometry using a FACS Canto II (BD Biosciences) using 
stably transfected CHO cells (e.g., CHO.PD-L1). Hybridomas 
were then be subcloned by limiting dilution into 96-well plates 
complete IMDM with 20% FBS and hybridoma fusion and clon-
ing supplement. Monoclonal cell lines were then screened by 
ELISA to select lines that produced the highest levels of mAbs. 
Anti-PD-1 and anti-PD-L1 mAbs were tested for their ability to 
FigUre 3 | alignment of PD-l2 amino acid sequence in eight mammalian species. The black-to-white color gradient indicates the degree of amino acid 
conservation among species, with black boxes indicating the most highly conserved sequence regions and white boxes indicating the most divergent regions for 
devil PD-L2. Dashes indicate gaps that have been introduced for best-fit multiple-sequence alignments. The putative extracellular domains, transmembrane 
domains, intracellular domains, and signal peptides are denoted by lines above the sequence.
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block receptor:coreceptor interactions (i.e., PD-1:PD-L1) using 
stably transfected cell lines (CHO.PD-1, CHO.PD-L1, and CHO.
PD-L2) and PD-1 fusion proteins.
assessment of PD-l1 on cell lines
DFT1.C5065, DFT1.1426, DFT1.4096, and DFT2.JV cells were 
cultured for 3  days with or without 5  ng/ml IFN-γ and then 
cultured for four additional days without IFN-γ. PD-L1 and 
PD-1 expression were quantified on days 1, 2, 3, and 7 by flow 
cytometry. Briefly, DFT cells were blocked with 5% normal goat 
serum in FACS buffer (PBS with 0.5% BSA, 0.05% NaN3) for 
15  min on ice in u-bottom 96-well plates, and then incubated 
with 1 μg/sample of anti-PD-L1 clone 1F8 or anti-PD-1 clone 
3G8 for 15  min on ice. The plates were then topped up with 
150 μl with FACS buffer and centrifuged at 500 g for 3 min at 
4°C. Samples were then incubated with 0.125 μg/sample of goat 
anti-mouse IgG-phycoerythrin (Abcam # AB98742) for 15 min. 
The plates were then topped up with 150 μl with FACS buffer and 
centrifuged at 500 g for 3 min at 4°C and then resuspended in 
FACS buffer prior to performing flow cytometric analysis using a 
FACS Canto II (BD Biosciences).
immunohistochemistry
Immunohistochemistry staining methods for the tissue sections 
used here have been previously reported in Kreiss (6), Tovar 
et al. (40) and Brown (41). Briefly, 3-μm slides were heated for 
10 min at 60°C prior to dewaxing in xylene for 5 min (2×) and 
then rehydrating in 100, 95, and 70% ethanol for 3  min each. 
Antigen retrieval was carried out by placing the slides in 0.1 M 
citric buffer in a sealed container and then heating in a pressure 
cooker for 6 min. The slides were then allowed to cool and rinsed 
with water before being immersed in 10% H2O2 for 10 min. The 
slides were then washed with PBS and non-specific binding was 
blocked using Dako protein block. Cell culture supernatant 
(1–5% IMDM) from α-PD-L1 hybridoma clone 1F8 and α-PD-1 
hybridoma clone 3G8 were used neat. The slides were then 
washed with PBS (2×) prior to adding Dako Envision + System 
HRP-labeled polymers and incubating for 30 min. The slides were 
FigUre 4 | PD-l1 mrna expression in PBMcs and devil facial tumor 
1 (DFT1) cells. Expression of PD-L1 in concanavalin A-stimulated PBMCs 
and DFT1 C5065 cells with and without IFN-γ treatment. The mRNA was 
reverse transcribed and expression of PD-L1 was tested via PCR. GAPDH 
was used as a reference gene and β2-microglobulin (B2m) was used as a 
positive control. The unstimulated tumors express only low levels of B2m and 
PD-L1 transcripts, but both B2m and PD-L1 expression increases following 
stimulation with IFN-γ. NTC, no template control. The rightmost lane in the 
gel contains the 1 kb DNA ladder.
FigUre 5 | confirmation of antibody specificity and blocking 
capacity. To assess the specificity and blocking capacity of devil-specific 
α-PD-L1 monoclonal antibodies (mAbs) CHO.PD-1 (a,D,g), CHO.PD-L1 
(B,e,h), and CHO.PD-L2 (c,F,i) transfected cells were preincubated with 
α-PD-L1 mAb clone 1F8 or isotype control antibodies prior to incubation with 
recombinant PD-1 fused to human IgG1-Fc (PD-1-Fc). Cells were then 
incubated with secondary anti-human IgG-Fc AlexaFluor 488 and anti-mouse 
IgG-phycoerythrin to detect PD-1-Fc binding and α-PD-L1 binding. Cells in 
the upper left quadrant indicate PD-1-Fc binding to the cell line and cells in 
the lower right indicate binding of mAbs to the cell line. Graphs (a–F) show 
that α-PD-L1 clone 1F8 binds to PD-L1, but not to PD-1 or PD-L2 and that 
clone 1F8 blocks binding of PD-1-Fc to PD-L1 but not to PD-L2. In order to 
asses blocking capacity of α-PD-1 mAbs, PD-1-Fc was preincubated with 
α-PD-1 mAb 3G8 prior to incubation with CHO.PD-1 (g), CHO.PD-L1 (h), 
or CHO-PD-L2 (i). Graphs (g–i) show that α-PD-1 clone 3G8 is specific for 
PD-1 and blocks binding of PD-1-Fc to both PD-L1 and PD-L2.
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again washed in PBS (2×). The Dako liquid DAB +  substrate 
chromogen system (Dako # K3468) was used according to the 
manufacturer’s instructions. Finally, slides were counterstained 
with Mayer Hematoxylin for 30  s before washing in running 
water for 4–5 min, washing for 4–5 min in running water, and 
submerging in 95% ethanol for 2 min, 100% ethanol for 2 min, 
and xylene for 2  min (2×). Slides were then coverslipped and 
stored in the dark until examination.
The cases of DFT2 were previously diagnosed in Pye et al. (3) 
by histopathology, cytogenetic analysis and detection of specific 
alleles at microsatellite and structural variant foci different to 
DFT1 and host DNA, and by PCR. DFT1 was diagnosed based 
on histopathological and immunohistochemical characteristics 
(40, 42).
resUlTs
alignment of PD-1, PD-l1, and PD-l2
To determine if PD-1, PD-L1, and PD-L2 have the potential to 
serve as inhibitory checkpoint molecules in Tasmanian devils as 
they do in other mammals, we first compared the devil amino 
acid sequences with sequences from several other mammalian 
species, including bat (Myotis davidii), cattle (Bos taurus), dog 
(Canis lupus familiaris), human (Homo sapiens), mouse (Mus 
musculus), opossum (Monodelphis domestica), and platypus 
(Ornithorhynchus anatinus) (Figures 1–3). Devil PD-1 has 37% 
sequence identity with human PD-1. The ICD of PD-1 contained 
putative ITIM and ITSM regions consistent with location and 
sequence of functional ITIMs and ITSMs in humans and mice 
(Figure  1); the devil PD-1 ITSM amino acid sequence was an 
exact match to human PD-1 ITSM, and the ITIM sequence dif-
fered by one amino acid between devils and humans. Alignments 
of PD-L1 showed 55% sequence identity with human PD-L1 
(Figure  2). The devil PD-L2 amino acid sequence has 48% 
sequence identity with human PD-L2 (Figure 3).
expression of PD-l1 mrna  
in PBMcs and DFT1
Prior to embarking on recombinant protein and mAb produc-
tion, we sought to establish if, like in better-characterized human 
and mouse tumor cell lines, devil tumor cells upregulate PD-L1 in 
response to IFN-γ treatment. PCR of cDNA from DFT1 cell line 
C5065 demonstrated that PD-L1 is not constitutively expressed in 
C5065, but that PD-L1 was strongly upregulated following IFN-γ 
treatment (Figure 4). As expected, B2m was also upregulated by 
IFN-γ (11).
PD-1 Binding to PD-l1 and PD-l2 and 
Blocking capacity of mabs
Our hybridoma development process yielded 10 α-PD-1 mAbs 
and 9 α-PD-L1 mAbs. Six of the nine α-PD-L1 mAbs could block 
binding of PD-1-Fc fusion proteins to CHO.PD-L1, but none 
of the α-PD-L1 mAbs blocked binding of PD-1 fusion proteins 
to CHO.PD-L2 (Figure  5). Five of the anti-PD-1 mAbs block 
binding of PD-1-Fc to both PD-L1 and PD-L2 (Figure  5) and 
two of the clones appear to partially block PD-L1 but not PD-L2 
(Figure S1 in Supplementary Material). See Table S2 in 
Supplementary Material for complete details for the α-PD-1 and 
α-PD-L1 panel of mAbs.
FigUre 7 | immunohistochemistry (ihc) of devil lymph nodes (ln). 
IHC of LN from a devil facial tumor 1 (DFT1) + devil (TD 374). The scale bar in 
the upper left of each ×10 image is 200 μm and the ×40 images are 50 μm. 
No tumor metastases were observed in the LN shown in this figure. PD-1 is 
expressed on 0–10% of lymphocytes in the cortical germinal centers but less 
than 1% of non-germinal center lymphocytes. PD-L1 expression is 
distributed throughout the cortex of the LN, but was detected on less than 
1% of lymphocytes (at ×40 objective).
FigUre 6 | iFn-γ induced expression of PD-l1 on devil facial tumor 1 (DFT1) and devil facial tumor 2 (DFT2). DFT1 cell lines 1426 (a), 4096 (B), 
and C5065 (c) and DFT2 cell line JV (D) were stimulated with 5 ng/ml of IFN-γ for 3 days, and PD-L1 surface expression was assessed on days 1, 2, 3, and 
7. PD-L1 surface expressions were highest at day 3 post-IFN-γ exposure, and PD-L1 returned to near baseline levels by day 7 (4 days after removal of IFN-γ). 
The arrow indicates when IFN-γ was removed from the culture. Gray histograms represent cells treated with IFN-γ and open (white) histograms represent 
untreated cells.
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In Vitro expression of PD-l1 on DFT cells
To confirm expression of PD-L1 on the surface of DFT cell lines, 
we stimulated four DFT cell lines (DFT1.C5065, DFT1.1426, 
DFT1.4096, and DFT2.JV) with IFN-γ for 3 days and then used 
flow cytometry to quantify PD-L1 expression on days 0, 1, 2, 3, 
and 7 using α-PD-L1 (1F8). All cell lines expressed little or no 
PD-L1 on day 0, but upregulated PD-L1 following IFN-γ treat-
ment (Figure 6). PD-L1 expression increased until day 3 when 
IFN-γ was removed from the cultures, but was still detectable 
on day 7, which is 4  days after IFN-γ was removed from the 
cultures. PD-1 was not expressed on either DFT1 or DFT2 with 
or without IFN-γ.
expression of PD-1 and PD-l1 in Devil 
Tissues
Several of the α-PD-1 and α-PD-L1 mAbs were capable of stain-
ing of FFPE tissue sections. Clones 3G8 and 1F8 were used for 
IHC because these clones also block PD-1:PD-L1 binding in 
flow cytometric assays and are thus the initial candidates for 
immunotherapy treatment of devil tumors. Low numbers of 
lymphocytes (1–2% of lymphocytes per high-powered field, that 
is at ×40 objective) in the outer cortex of LN generally demon-
strated positive cytoplasmic staining for PD-L1. A few germinal 
centers contained 5–10% PD-L1+ lymphocytes per high-powered 
field (at ×40 objective) (Figure 7). PD-1 was rarely detected in 
lymph node structures other than germinal centers. We screened 
tumor-containing tissue sections from 18 devils via IHC that were 
either naturally infected (n = 12) or experimentally inoculated 
(n = 5) with tumors as part of a different study (1) and found 
that PD-L1 was generally not expressed in DFT1 (Figure 8) or 
DFT2 (Figure 9) cells except for a few sporadic cells. Twenty out 
of 33 tumor-containing tissue sections contained one or more 
PD-L1+ cells, with the majority of sections containing less than 20 
PD-L1+ cells. Low numbers of PD-L1+ lymphocytes, plasma cells, 
and macrophages were detected in the fibrovascular interstitium, 
renal cortical interstitium, cortex and medulla of LN, and peri-
bronchiolar connective tissue near or within tumors in the facial 
region, kidneys, LN, and lungs, respectively. Interestingly, groups 
of PD-1+ cells were detected in lung tissue of a devil with DFT2 
metastases in the lung (Figure 10). See Table S3 in Supplementary 
Material for a summary of IHC findings.
DiscUssiOn
The transmissible DFTD represents an immunological enigma 
due to the fact that these transmissible tumor allografts are 
not recognized and rejected as foreign. This is despite genetic 
differences between the host and tumor and the high muta-
tional load that has accumulated in the DFT1 in 20  years of 
host-to-host transmission (9). In humans and mice, expression 
of PD-L1 on tumor cells represents a powerful immune evasion 
FigUre 9 | immunohistochemistry (ihc) of the fibrovascular 
interstitium of devil facial tumor 2 (DFT2) tissue. IHC images of tissue 
sections from a DFT2 tumor mass removed from TD 500. The scale bar in 
the upper left of each ×10 image is 200 μm and the ×40 images are 50 μm. 
Low numbers of plasma cell-like cells with positive cytoplasmic staining for 
PD-L1 were detected within the fibrovascular interstitium and not infiltrating 
within tumor packets using the ×10 and ×40 objectives. PD-1+ cells were 
rare throughout the tissue, with only two PD-1+ cell detected in the image 
above. Periaxin (PRX) is shown here for comparative purposes only, as the 
DFT2 cells do not express PRX.
FigUre 8 | immunohistochemistry (ihc) devil facial tumor 1 (DFT1) 
tissue. IHC images of DFT1 tissue sections from TD 512 using the ×10 and 
×40 objectives. The scale bar in the upper left of each ×10 image is 200 μm 
and the ×40 images are 50 μm. The bottom row is stained with α-Periaxin, 
which is used to identify DFT1 cells. PD-L1 was occasionally detected on 
tumor cells but was more commonly detected in low numbers of 
lymphocytes, plasma cells, and macrophages within the fibrovascular stroma 
supporting multiple lobules within the tumor.
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pathway commonly employed by tumor cells, but the role of 
PD-1 and PD-L1 had not been previously investigated in devils 
and transmissible tumors. Here, we provide the first evidence 
in a non-placental mammalian species that the inhibitory cell 
surface signaling molecule PD-1 binds to PD-L1 and PD-L2 
and that PD-L1 is strongly upregulated on DFT1 and DFT2 
cells in response to IFN-γ emphasizing the conserved nature of 
this signaling module across a range of evolutionarily disparate 
species.
Analysis of the PD-1 protein sequence revealed putative ITIM 
and ITSM domains, which are critical for the inhibitory effects of 
PD-1 observed in other species. Their conservation suggests that 
PD-1 may serve as a negative regulator to immune cells in devils 
as it does in humans and mice. The devil PD-1 ITSM sequence was 
a perfect match to human, dog, bat, and cattle PD-1 ITSM, and 
the ITIM sequence varied by only a single amino acid, suggesting 
that strong selective pressure has maintained these motifs across 
the 160 million years since marsupials and placental mammals 
diverged (43). Further research is needed to confirm the inhibi-
tory function of devil ITSMs and ITIMs.
In humans and mice, PD-L1 and PD-L2 have different expres-
sion patterns and functional effects upon PD-1 binding (44). The 
panel of dual blocking, single blocking, and non-blocking mAbs 
developed here will allow us to explore the functional roles of 
PD-1, PD-L1, and PD-L2 in devils and may help to shed light on 
immune evasion by cancers and the role of PD-1 and PD-L1 in 
allograft rejection that is relevant to humans and other species. 
For instance, the devil immune system rejects skin allografts 
but not skin autografts or tumor allografts (8), thus suggesting 
that the tumor cells evade an allo-antigen immune response. As 
DFTs are primarily transmitted through biting, it is likely that 
tissue damage is associated with at least some of the transmission 
events. This could result in an “immune-active” environment and 
upregulation of PD-L1 (45). Transplantation of DFT1 and DFT2 
FigUre 10 | immunohistochemistry (ihc) lung tissue with devil facial 
tumor 2 (DFT2) metastases. IHC images of lung tissue from TD467. DFT2 
metastases are not visible in the images shown here. The scale bar in the 
upper left of each ×10 image is 200 μm and the ×40 images are 50 μm. The 
lungs contained low numbers of lymphocytes with positive cytoplasmic 
staining for PD-1, but the lymphocytes are predominantly peribronchiolar and 
not near tumor metastases. PD-L1 was not detected on tumor cells and was 
rare on non-tumor cells.
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to hosts with varying degrees of genetic relatedness could shed 
light on the importance of PD-L1 in tissue damage and inflamma-
tion during the early stages of allograft tolerance or rejection and 
tumor transmission and development. Furthermore, the study of 
allograft tumors in humans is only possible when tumor cells are 
unwittingly transplanted into a new host along with the target 
transplant tissue (46). The clonal transmissibility of the DFTs 
allows for natural serial transfer experiments using cells that have 
never been cultured in vitro, which could have lasting effects on 
tumor phenotype, and also facilitates assessment of the roles of 
PD-1, PD-L1, and PD-L2 in tumor transmission, development, 
and metastases. Finally, recent evidence suggests that some devils 
can mount an immune response to DFT tumors (47), and the 
new reagents developed here could clarify the role of PD-L1 in 
responders versus non-responders.
In humans, PD-1 is transiently upregulated following activa-
tion of naïve T cells, and its expression decreases as the antigen 
is cleared, but PD-1 expression can be sustained during chronic 
infections [reviewed in Ref. (22)]. DFTD is essentially a chronic 
infection that usually kills infected devils within 6–12  months 
(48), during which time tumor antigens would be abundantly 
expressed. In the LN that we examined via IHC, PD-1 was 
generally expressed on 1–2% of lymphocytes in lymph node 
germinal center cells, which is consistent with patterns that have 
been reported in humans (49–53) and rhesus macaques (Macaca 
mulatta) (54, 55). Unfortunately, because devils are an endan-
gered species, we only had LN from unhealthy devils and thus 
were unable to compare PD-1 and PD-L1 expression patterns 
between healthy and diseased devils at this time.
Our in  vitro results demonstrate that IFN-γ transiently 
upregulates PD-L1 on both DFT1 and DFT2 cell lines. Our IHC 
results are in agreement with the in vitro results showing that 
both DFT1 and DFT2 cells do not normally express PD-L1 or 
express very low levels of PD-L1. This is not surprising given 
that tumor-infiltrating lymphocytes (TILs) are rarely observed 
in DFT1 or DFT2 tumors, so local production of IFN-γ by T 
cells is likely absent in most cases (11, 56, 57). Additionally, 
upregulation of PD-L1 in response to IFN-γ lasts only a few 
days. However, as immunity to the tumor cells may be compart-
mentalized in the draining LN and tumor microenvironment, 
tumor metastases to new locations might induce an inflam-
matory response that could result in transient upregulation of 
PD-L1. We did observe PD-L1+ non-tumor cells in the tumor 
microenvironment of several metastatic tumors and scattered 
PD-L1+ tumor cells.
In humans, the combination of α-CTLA4 and α-PD-1 has 
generally proven much more effective that either treatment alone 
(58–60). α-CTLA4 treatment is particularly useful in PD-L1-
negative tumors with a high number of neoantigens in which the 
α-CTLA4 treatment is hypothesized to enhance T cell activation 
and increase the probability of TILs and stimulate IFN-γ pro-
duction, at which point combination treatment with α-PD-1 or 
α-PD-L1 becomes critical for amplifying and maintaining the 
antitumor response (61, 62). Additional research is needed to 
determine if CTLA4 serves as an inhibitory checkpoint molecule 
in marsupials and also if the CD80 binds to both CTLA4 and 
PD-L1 as it does in humans and mice (63).
In conclusion, this study is the first to show that receptor–
ligand interactions between the potent cosignalling molecules 
PD-1, PD-L1, and PD-L2 are conserved in marsupials. Analysis 
of PD-1 protein sequence revealed putative ITIM and ITSM 
domains, which are critical for the inhibitory effects of PD-1 
observed in other species. We report that PD-L1 expression is 
rare on both DFT1 and DFT2 cells, but that PD-L1 expression 
is upregulated by treatment with IFN-γ. Mapping the complex 
interactions and expression patterns of inhibitory checkpoint 
molecules will be critical for developing a DFTD vaccine and 
understanding how transmissible tumors evade host immune 
responses. Understanding the immune evasion mechanisms 
employed by these transmissible tumors could help to shed 
light not only on cancer immunology but also for transplant 
tolerance in many species including humans. Finally, the cur-
rent iteration of the DFT disease vaccine uses DFT cells that 
have been stimulated with IFN-γ to upregulate MHC I prior 
to killing the cells and injecting with adjuvant. This treatment 
has proven effective at stimulating both humoral and cytotoxic 
responses against tumor cells and has provided short-term 
protection against tumor challenge (7). The results reported 
here demonstrate that the PD-L1 is strongly upregulated by 
IFN-γ and thus blocking PD-L1 prior to administration of 
the vaccine, or administering α-PD-1 or α-PD-L1 in conjunc-
tion with the vaccine, could augment antitumor responses by 
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the devil immune system. Additionally, as both prophylactic 
and therapeutic DFTD vaccines are high priority, the results 
presented here represent an important first step toward under-
standing the complex network of molecular signaling that is 
necessary for the foreign tissue grafts to avoid being killed by 
host immune defenses.
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